|
"tsai t h"的相關文件
顯示項目 296-305 / 489 (共49頁)
<< < 25 26 27 28 29 30 31 32 33 34 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2020-01-13T08:23:08Z |
Applications of nanofluids in microfluidic devices
|
Chen, P.-H.; Liou, D.-S.; Tsai, T.-H.; Kuo, L.-S.; Yang, C.-T.; PING-HEI CHEN |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yu C.-J.; Yang J.C.-H.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2019-12-27T01:15:09Z |
Resonance-enhanced functional third harmonic optical microscopy
|
Chu, S.-W.;Chen, S.-Y.;Tsai, T.-H.;Liu, T.-M.;Wu, S.-B.;Biring, S.;Wang, J.-K.;Wang, Y.-L.;Chen, K.;Lin, B.-L.;Sun, C.-K.; Chu, S.-W.; Chen, S.-Y.; Tsai, T.-H.; Liu, T.-M.; Wu, S.-B.; Biring, S.; Wang, J.-K.; Wang, Y.-L.; Chen, K.; Lin, B.-L.; Sun, C.-K.; SHI-WEI CHU |
| 臺大學術典藏 |
2019-12-26T08:00:52Z |
Spectral evidence on the plasmon-resonant enhanced third-harmonic χ (3) of Ag nanoparticles
|
Liu, T.-M.;Tal, S.-P.;Chu, S.-W.;Tsai, T.-H.;Chen, S.-Y.;Shi, X.-Y.;Chang, C.-H.;Wu, Y.;Shieh, D.-B.;Chen, L.-J.;Prasad, M.R.;Lin, K.-J.;Sun, C.-K.; Liu, T.-M.; Tal, S.-P.; Chu, S.-W.; Tsai, T.-H.; Chen, S.-Y.; Shi, X.-Y.; Chang, C.-H.; Wu, Y.; Shieh, D.-B.; Chen, L.-J.; Prasad, M.R.; Lin, K.-J.; Sun, C.-K.; SHI-WEI CHU |
| 臺大學術典藏 |
2019-12-20T01:18:32Z |
On Higgs branch localization of Seiberg-Witten theories on an ellipsoid
|
Chen, H.-Y.;Tsai, T.-H.; Chen, H.-Y.; Tsai, T.-H.; HENG-YU CHEN |
| 臺大學術典藏 |
2019-12-19T08:37:59Z |
Three-dimensional skin imaging using the combination of reflected confocal and multiphoton microscopy
|
Lin, M.-G.; Chen, W.-L.; Lo, W.; Tan, H.-Y.; Tsai, T.-H.; Jee, S.-H.; Lin, S.-J.; Dong, C.-Y.; CHEN-YUAN DONG |
| 臺大學術典藏 |
2019-12-19T08:37:57Z |
Investigation of the mechanism of transdermal penetration enhancer: A comparison of multiphoton microscopy and electron microscopy
|
Lin, S.-J.;Lee, J.-N.;Lin, C.-Y.;Chan, C.-C.;Lin, M.-G.;Wang, C.-C.;Tan, H.-Y.;Tsai, T.-H.;Jee, S.-H.;Dong, C.-Y.; Lin, S.-J.; Lee, J.-N.; Lin, C.-Y.; Chan, C.-C.; Lin, M.-G.; Wang, C.-C.; Tan, H.-Y.; Tsai, T.-H.; Jee, S.-H.; Dong, C.-Y.; CHEN-YUAN DONG |
顯示項目 296-305 / 489 (共49頁)
<< < 25 26 27 28 29 30 31 32 33 34 > >>
每頁顯示[10|25|50]項目
|
